Vascular Endothelial Growth Factor Receptor-2
"Vascular Endothelial Growth Factor Receptor-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF.
| Descriptor ID |
D040301
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.950.200 D12.776.543.750.630.750.200 D12.776.543.750.750.400.910.200
|
| Concept/Terms |
Vascular Endothelial Growth Factor Receptor-2- Vascular Endothelial Growth Factor Receptor-2
- Vascular Endothelial Growth Factor Receptor 2
- KDR Tyrosine Kinase
- Tyrosine Kinase, KDR
- VEGFR-2
- Fetal Liver Kinase-1
- Fetal Liver Kinase 1
- Kinase Insert Domain Receptor
- VEGF Receptor Flk-1
- Flk-1, VEGF Receptor
- VEGF Receptor Flk 1
- VEGF Receptor KDR
- KDR, VEGF Receptor
- Flk-1 Protein
- Flk 1 Protein
- Flk-1 Receptor Tyrosine Kinase
- Flk 1 Receptor Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor Receptor-2".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor Receptor-2".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor Receptor-2" by people in this website by year, and whether "Vascular Endothelial Growth Factor Receptor-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 5 | 6 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 5 | 6 |
| 2011 | 1 | 2 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 2 | 3 |
| 2022 | 0 | 3 | 3 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor Receptor-2" by people in Profiles.
-
Circulating Progenitor Cells, Regenerative Capacity and Cognition: Evidence From 2 Community-Based Cohorts. Arterioscler Thromb Vasc Biol. 2026 Jul; 46(7):e323805.
-
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. Clin Cancer Res. 2022 06 01; 28(11):2229-2236.
-
Angiosarcoma of the Pancreas in a Pediatric Patient With an Activating KDR-Internal Tandem Duplication: A Case Report and Review of the Literature. J Pediatr Hematol Oncol. 2022 Apr 01; 44(3):e751-e755.
-
TFEB controls vascular development by regulating the proliferation of endothelial cells. EMBO J. 2019 02 01; 38(3).
-
Intravitreal Stanniocalcin-1 Enhances New Blood Vessel Growth in a Rat Model of Laser-Induced Choroidal Neovascularization. Invest Ophthalmol Vis Sci. 2018 02 01; 59(2):1125-1133.
-
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Sep; 62(9):1562-6.
-
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014 Jul 15; 20(14):3849-61.
-
Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther. 2014 Apr; 14(4):367-79.
-
KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development. Cell Stem Cell. 2013 Jun 06; 12(6):748-60.
-
Ramucirumab: a novel antiangiogenic agent. Future Oncol. 2013 Jun; 9(6):789-95.